---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-212358"
form_type: "8-K"
ticker: "TCRT"
cik: "0001107421"
company_name: "Alaunos Therapeutics, Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T10:01:23.187657+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Alaunos Therapeutics winds down TCR-T trial, cuts workforce 60%, explores strategic alternatives

## Summary
- Q2 2023 net loss $8.8M ($0.04 per share); cash $18.3M, expected to fund ops into Q4 2023.
- Wind-down of TCR-T Library Phase 1/2 trial; 83% disease control rate in 6 evaluable patients.
- Workforce reduction of ~60%; retains key hunTR platform R&D capabilities.
- Engaged Cantor Fitzgerald to explore strategic alternatives including sale, merger, or partnerships.

## SEC filing metadata
- accession: 0001193125-23-212358
- form_type: 8-K
- ticker: TCRT
- cik: 0001107421
- company_name: Alaunos Therapeutics, Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1107421/000119312523212358/0001193125-23-212358-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1107421/000119312523212358/d467190d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-212358
- JSON: https://secwatch.observer/filing/0001193125-23-212358.json
- Plain text: https://secwatch.observer/filing/0001193125-23-212358.txt

## Key facts
- Earnings Releases
  Alaunos Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss was $8.8 million, or $(0.04) per share, EPS $(0.04) per share.
  - Period: the second quarter ended June 30, 2023
  - Net income: Net loss was $8.8 million, or $(0.04) per share
  - EPS: $(0.04) per share
  - Result: reported results
  source text: On August 14, 2023, Alaunos Therapeutics, Inc. (the “Company”) issued a press release announcing financial results for the three and six months ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000119312523212358/0001193125-23-212358-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.